BIOSECURE Act Restricts US Biotech Procurement as China Supplies 45% of Drug Ingredients
Updated
Updated · Fox News · Sep 14
BIOSECURE Act Restricts US Biotech Procurement as China Supplies 45% of Drug Ingredients
1 articles · Updated · Fox News · Sep 14
Summary
December 2025’s BIOSECURE Act bars federal procurement involving biotechnology products from designated companies tied to foreign adversaries, framing drug supply as a national-security issue rather than only a trade concern.
China produces about 45% of the world’s active pharmaceutical ingredients, while the United States makes roughly 3%; a Johns Hopkins study said China supplies more than 60% of essential components US manufacturers need for antibiotics.
Robert F. Kennedy Jr. argued that decades of offshoring created a structural dependency that could let Beijing disrupt access to medicines or compromise product safety, echoing broader fears after China’s use of leverage in other supply chains.
The report says the law alone will not rebuild capacity, urging heavy investment in domestic pharmaceutical plants and citing Ohio’s manufacturing base as a model for reshoring critical drug production.